South Korea Cancer Immunotherapy Market PPT 2024: Size, Growth, Demand and Forecast till 2032
                     South Korea Cancer 
Immunotherapy Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " S o u t h  K o r e a  C a n c e r  I m m u n o t h e r a p y  
M a r k e t :  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 -
2 0 3 2 , "  t h e  S o u t h  K o r e a  c a n c e r  i m m u n o t h e r a p y  m a r k e t  s i z e  i s  p r o j e c t e d  t o  e x h i b i t  a  g r o w t h  
r a t e  ( C A G R )  o f  8 . 3 0 %  d u r i n g  2 0 2 4 - 2 0 3 2 .
T h e  S o u t h  K o r e a  c a n c e r  i m m u n o t h e r a p y  m a r k e t  i s  w i t n e s s i n g  s i g n i f i c a n t  g r o w t h ,  p r i m a r i l y  
Report d r i v e n  b y  t h e  c o u n t r y ' s  i n c r e a s i n g  c a n c e r  b u r d e n  a n d  t h e  s h i f t  t o w a r d s  m o r e  t a r g e t e d  a n d  
e f f e c t i v e  t r e a t m e n t  m o d a l i t i e s .  I n  a d d i t i o n  t o  t h i s ,  t h e  e x p a n d i n g  h e a l t h c a r e  i n f r a s t r u c t u r e  i n  
S o u t h  K o r e a ,  a l o n g  w i t h  g r o w i n g  i n v e s t m e n t s  i n  R & D ,  c r e a t i n g  a n  i d e a l  e n v i r o n m e n t  f o r  t h e  
Highlight and a d o p t i o n  o f  i m m u n o t h e r a p y  t r e a t m e n t s ,  i s  f u r t h e r  s t i m u l a t i n g  t h e  m a r k e t  g r o w t h .  
T h e s e  t r e a t m e n t s ,  w h i c h  u s e  t h e  b o d y ' s  i m m u n e  s y s t e m  t o  f i g h t  c a n c e r ,  a r e  g a i n i n g  
p r o m i n e n c e  d u e  t o  t h e i r  p o t e n t i a l  t o  o f f e r  m o r e  p e r s o n a l i z e d  a n d  l e s s  t o x i c  a l t e r n a t i v e s  t o  
Description t r a d i t i o n a l  c a n c e r  t r e a t m e n t s  s u c h  a s  c h e m o t h e r a p y  a n d  r a d i a t i o n  t h e r a p y .  B e s i d e s  t h i s ,  t h e  
r i s i n g  p r e v a l e n c e  o f  v a r i o u s  c a n c e r s  i n  S o u t h  K o r e a ,  i n c l u d i n g  l u n g ,  b r e a s t ,  a n d  g a s t r i c  
c a n c e r s ,  i s  f u r t h e r  f u e l i n g  t h e  d e m a n d  f o r  i n n o v a t i v e  t r e a t m e n t  o p t i o n s .  A d d i t i o n a l l y ,  t h e  
g r o w i n g  p o p u l a r i t y  o f  i m m u n o t h e r a p y  d u e  t o  i t s  e f f e c t i v e n e s s  i n  m a n a g i n g  c e r t a i n  t y p e s  o f  
c a n c e r  t h a t  h a v e  b e e n  c h a l l e n g i n g  t o  t r e a t  i s  c r e a t i n g  a  p o s i t i v e  o u t l o o k  f o r  t h e  m a r k e t .
R e q u e s t  f o r  a  P D F  s a m p l e  o f  t h i s  r e p o r t :  
h t t p s : / / w w w . i m a r c g r o u p . c o m / s o u t h - k o r e a - c a n c e r - i m m u n o t h e r a p y - m a r k e t / r e q u e s t s a m p l e
Report Description
South  Korea  Cancer  Immunotherapy Market  Trends:
Moreover ,  the  inc reas ing co l laborat ion  between pharmaceut ica l  companies ,  research  ins t i tu t ions,  and  
hosp i ta ls  to  deve lop and  commerc ia l ize  new immunotherapy d rugs,  is  ac t ing  as  ano ther  s ign i f icant  g rowth-
induc ing  fac tor .  These co l laborat ions  a re  no t  on ly  acce le ra t ing the  ava i lab i l i t y  o f  cu t t ing -edge t rea tments  bu t  
a lso  pos i t ion ing  South  Korea as  a  key p layer  in  the  g loba l  cancer  immunotherapy  marke t .  
Apar t  f rom th is ,  the  in t roduct ion  o f  nove l  immunotherapeut ic  agen ts ,  inc lud ing  checkpo in t  inh ib i to rs ,  CAR-T  
ce l l  therap ies ,  and cancer  vacc ines ,  i s  fu r ther  s t imula t ing the  marke t  g rowth .  Add i t iona l l y ,  the ongo ing  e f fo r ts  
to  in tegra te  b ig  da ta  and  ar t i f i c ia l  in te l l igence  in  hea l thcare  to  enhance the  e f f i cacy  and prec is ion o f  
immunotherapy  t rea tments ,  ta i lo r  therap ies  to  ind iv idua l  pa t ients '  gene t ic  pro f i les ,  and  improve  c l in ica l  
ou tcomes a re  expec ted  to  d r ive  the South  Korea  cancer  immunotherapy marke t  in  the coming years .
View Report  TOC,  F igures  and Tables :  
ht tps: / /www. imarcgroup.com/south-korea-cancer- immunotherapy-market
Therapy Type Insights:
• Monoclonal  Ant ibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators
• Others
Report 
Application Insights:
Segmentation • Lung Cancer
• Breast Cancer
• Colorectal  Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Others
End User Insights:
• Hospitals
• Cancer Research Centers
• Clinics
• Others
Report Regional Insights:
Segmentation • Seoul Capital  Area
• Yeongnam (Southeastern Region)
• Honam (Southwestern Region)
• Hoseo (Central  Region)
• Others
How has the South Korea cancer immunotherapy market 
performed so far and how will it perform in the coming 
years?
What has been the impact of COVID-19 on the South Korea 
cancer immunotherapy market?
What is the breakup of the South Korea cancer 
immunotherapy market on the basis of therapy type?
Key 
What is the breakup of the South Korea cancer 
immunotherapy market on the basis of application?
Questions 
What is the breakup of the South Korea cancer 
Answered in immunotherapy market on the basis of end user?
the Report What are the various stages in the value chain of the South Korea cancer immunotherapy market?
What are the key driving factors and challenges in the South 
Korea cancer immunotherapy?
What is the structure of the South Korea cancer 
immunotherapy market and who are the key players?
What is the degree of competition in the South Korea cancer 
immunotherapy market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    S o u t h  K o r e a  C a n c e r  I m m u n o t h e r a p y  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    S o u t h  K o r e a  C a n c e r  I m m u n o t h e r a p y  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    S o u t h  K o r e a  C a n c e r  I m m u n o t h e r a p y  M a r k e t  -  B r e a k u p  b y  T h e r a p y  T y p e
    6 . 1     M o n o c l o n a l  A n t i b o d i e s
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     C a n c e r  V a c c i n e s
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
    6 . 3     C h e c k p o i n t  I n h i b i t o r s
        6 . 3 . 1  O v e r v i e w
        6 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 4     I m m u n o m o d u l a t o r s
        6 . 4 . 1  O v e r v i e w
        6 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 5     O t h e r s
        6 . 5 . 1  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 5 . 2  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
Table of 7    S o u t h  K o r e a  C a n c e r  I m m u n o t h e r a p y  M a r k e t  -  B r e a k u p  b y  A p p l i c a t i o n
    7 . 1     L u n g  C a n c e r
        7 . 1 . 1  O v e r v i e w
Contents         7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 2     B r e a s t  C a n c e r
        7 . 2 . 1  O v e r v i e w
        7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 3     C o l o r e c t a l  C a n c e r
        7 . 3 . 1  O v e r v i e w
        7 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 4     M e l a n o m a
        7 . 4 . 1  O v e r v i e w
        7 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /s o u t h -ko rea - c a nc e r- im m uno t he r
a py-m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: